Background Image
Previous Page  165 / 182 Next Page
Information
Show Menu
Previous Page 165 / 182 Next Page
Page Background

164

http://www.DGS-PraxisLeitlinien.de

Nr.

Nachweis

153

Lennernäs B, Frank-Lissbrant I, Lennernäs H, Kälkner KM, Derrick R, Howell J. Sublingual

administration of fentanyl to cancer patients is an effective treatment for breakthrough

pain: results from a randomized phase II study. Palliat Med 2010; 24(3): 286-293.

154

Lennernäs B, Hedner T, Holmberg M, Bredenberg S, Nyström C, Lennernäs H. Pharma-

cokinetics and tolerability of different doses of fentanyl following sublingual administ-

ration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of

incident pain. Br J Clin Pharmacol 2005; 59(2): 249-253.

155

Leppert W. Role of intranasal fentanyl in breakthrough pain management in cancer

patients. Cancer Manag Res 2010; 2: 225-232.

156

Locker GJ. Durchbruchschmerzen. Der Mediziner 2011; 9: 6-8.

157

Loeser B, Zöllner C. Durchbruchschmerzen bei Tumor- und Nicht-Tumorpatienten.

Münchner Med Wochenschrift 2011; 23: 86-89.

158

Lossignol DA, Dumitrescu C. Breakthrough pain: progress in management. Curr Opin

Oncol 2010; 22(4): 302-306.

159

Lyseng-Williamson KA. Fentanyl pectin nasal spray: in breakthrough pain in opioid-

tolerant adults with cancer. CNS Drugs 2011; 25(6): 511-522.

160

Mahar PJ, Rana JA, Kennedy CS, Christopher NC. A randomized clinical trial of oral trans-

mucosal fentanyl citrate versus intravenous morphine sulfate for initial control of pain

in children with extremity injuries. Pediatr Emerg Care 2007; 23(8): 544-548.

161

Mahfudh SS. Nurse's role in controlling cancer pain. J Pediatr Hematol Oncol 2011; 33

(Suppl. 2): S146-148.

162

Malone BT, Beye R, Walker J. Management of pain in the terminally ill by administration

of epidural narcotics. Cancer 1985; 55: 438-440.

163

Manchikanti L, Singh V, Caraway DL, Benyamin RM. Breakthrough pain in chronic non-

cancer pain: fact, fiction, or abuse. Pain Physician 2011; 14: E103-E117.

164

Melzack R. The short-form McGill pain questionnaire. Pain 1987; 30: 191-197.

165

Mercadante S, Arcuri E, Ferrera P, Villari P, Mangione S. Alternative treatments of break-

through pain in patients receiving spinal analgesics for cancer pain.  Journal of Pain and

Symptom Management 2005; 30(5): 485-491.

166

Mercadante S, Arcuri E. Breakthrough pain in cancer patients: pathophysiology and

treatment. Cancer Treatment Reviews 1998; 24: 425-432.

167

Mercadante S, Ferrera P, Adile C, Casuccio A. Fentanyl buccal tablets for breakthrough

pain in highly tolerant cancer patients: preliminary data on the proportionality between

breakthrough pain dose and background dose. J Pain Symptom Manage 2011; 42(3):

464-469.

168

Mercadante S, Ferrera P, Arcuri E. The use of fentanyl buccal tablets as breakthrough

medication in patients receiving chronic methadone therapy: an open label preliminary

study. Support Care Cancer 2011; 19(3): 435-438.

Literaturverzeichnis